Biotechnology

Aligos Therapeutics

Sio Capital Management LLC Increased Holdings in Aligos Therapeutics

Aligos Therapeutics Reports Positive Data for Pevifoscorvir Sodium in Chronic Hepatitis B Treatment

Aligos Therapeutics released FY2025 9 Months Earnings on November 6 Pre-Market EST, with actual revenue of USD 2.017 M and EPS of USD -6.6838

Aligos Therapeutics released FY2025 Q3 earnings on November 6 Pre-Market (EST), actual revenue USD 741 K (forecast USD 333.33 K), actual EPS USD -3.0413 (forecast USD -1.9)

Aligos Therapeutics to Release FY2025 Q3 Earnings on November 6, Pre-Market EST; Forecast Revenue USD 500K, EPS USD -1.9

Trucchio covers Aligos Therapeutics stock

Trucchio analyzes Arrowhead Pharmaceuticals and other healthcare industry stocks

Weiss Ratings Reiterates Sell Rating on Aligos Therapeutics

Aligos Therapeutics released FY2025 Q2 earnings on August 6 After-Market EST, actual revenue USD 965 K (forecast USD 433.33 K), actual EPS USD -1.5324 (forecast USD -2.3633)

Aligos Therapeutics released FY2025 Semi-Annual Earnings on August 6 After-Market EST, with actual revenue of USD 1.276 M and EPS of USD 2.9

Aligos Therapeutics to release FY2025 Q2 earnings on August 6 After-Market EST, forecast revenue USD 433.33 K, EPS USD -2.3633

Aligos Grants 2,100 Non-qualified Stock Options to New Hires

Aligos Therapeutics Shareholders Approve Multiple Company Proposals

Aligos Therapeutics released FY2025 Q1 earnings on May 6 Pre-Market EST, actual revenue USD 311K (forecast USD 500K), actual EPS USD -2.1099 (forecast USD -2.9775)

Aligos Therapeutics Inc reports Q1 loss of $2.80 per share, 66.2% revenue decline

Aligos Therapeutics to Release FY2025 Q1 Earnings on May 6, Pre-Market EST; Forecast Revenue USD 333.33K, EPS USD -2.7966

Aligos Therapeutics to present eight abstracts at the EASL Congress

Aligos Therapeutics Inc Submits Application to SEC to Offer Up to 6.2 Million Shares of Common Stock

Aligos Therapeutics Presents Positive Data on Innovative Liver and Viral Disease Treatments at the Asia-Pacific Association for the Study of the Liver Annual Meeting

Aligos Therapeutics released FY2024 Annual Earnings on March 10 Pre-Market (EST), actual revenue $3.945M (forecast $3.744M), actual EPS -$20.9447 (forecast -$10.0933)

Republic Power

Brand Engagement Network

Society Pass

Intelligent Living Application

3 E Network Tech

Globavend

CCSC Tech

Sidus Space

Tryhard

Dreamland

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap